



“Chronic thromboembolic pulmonary hypertension in Saudi Arabia: preliminary results from the SAUDIPH registry”. Abdullah M. Aldalaan, Sarfraz A. Saleemi, Ihab Weheba, Abeer Abdelsayed, Pekka Hämmäinen, Maha M. Aleid, Fatima Alzubi, Hamdeia Zaytoun and Nadeen Alharbi. *ERJ Open Res* 2019; 6: 00218-2019.

This article was originally published with an error in the “Treatment and follow-up” subsection of the results:

“In terms of pharmacological treatment, at the last follow-up visit, 7.9% of patients were on single pulmonary hypertension-specific treatment (mostly macitentan or sildenafil) and 20.6% were on combination pulmonary hypertension-specific treatment (mostly macitentan plus sildenafil) (table 3).”

has now been corrected to:

“In terms of pharmacological treatment, at the last follow-up visit, 29.7% of patients were on single pulmonary hypertension-specific treatment (mostly macitentan or sildenafil) and 20.6% were on combination pulmonary hypertension-specific treatment (mostly macitentan plus sildenafil) (table 3).”

in the article itself.

ERJ Open Res 2020; In press | DOI: 10.1183/23120541.50218-2019 | Copyright ©ERS 2020.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

